Enlivex (ENLV)

Develops Allocetra, an off-the-shelf apoptotic-cell therapy designed to reprogram macrophages toward homeostasis. Clinical Operations focus almost exclusively on intra-articular treatment for age-related symptomatic knee osteoarthritis, with a randomized trial underway in the United States and European Union. The Israel-based team must generate adequate safety, pain, function, and durability evidence before the candidate can be commercialized.

Manages a digital-asset treasury centered on RAIN, the governance and utility token for a decentralized prediction- and options-markets protocol. Treasury Operations hold and manage RAIN and related instruments; their financial outcomes depend principally on fair-value movements rather than customer fees. Allocetra has no marketing approval, and RAIN is the primary treasury reserve asset.